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Abstract
Background: Immunocompromised patients are vulnerable to severe or complicated influenza infection. Vaccination is
widely recommended for this group. This systematic review and meta-analysis assesses influenza vaccination for
immunocompromised patients in terms of preventing influenza-like illness and laboratory confirmed influenza, serological
response and adverse events.
Methodology/Principal Findings: Electronic databases and grey literature were searched and records were screened
against eligibility criteria. Data extraction and risk of bias assessments were performed in duplicate. Results were
synthesised narratively and meta-analyses were conducted where feasible. Heterogeneity was assessed using I2 and
publication bias was assessed using Begg’s funnel plot and Egger’s regression test. Many of the 209 eligible studies included
an unclear or high risk of bias. Meta-analyses showed a significant effect of preventing influenza-like illness (odds ratio
[OR] = 0.23; 95% confidence interval [CI] = 0.16–0.34; p,0.001) and laboratory confirmed influenza infection (OR = 0.15; 95%
CI = 0.03–0.63; p = 0.01) through vaccinating immunocompromised patients compared to placebo or unvaccinated controls.
We found no difference in the odds of influenza-like illness compared to vaccinated immunocompetent controls. The
pooled odds of seroconversion were lower in vaccinated patients compared to immunocompetent controls for seasonal
influenza A(H1N1), A(H3N2) and B. A similar trend was identified for seroprotection. Meta-analyses of seroconversion
showed higher odds in vaccinated patients compared to placebo or unvaccinated controls, although this reached
significance for influenza B only. Publication bias was not detected and narrative synthesis supported our findings. No
consistent evidence of safety concerns was identified.
Conclusions/Significance: Infection prevention and control strategies should recommend vaccinating immunocompro-
mised patients. Potential for bias and confounding and the presence of heterogeneity mean the evidence reviewed is
generally weak, although the directions of effects are consistent. Areas for further research are identified.
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Introduction
Respiratory disease is a leading cause of global mortality to
which seasonal and pandemic influenza both make substantial
contributions. For example, in the USA an estimated average
225,000 hospitalisations and 36,000 deaths per annum are
attributable to seasonal influenza [1,2]. Even the ‘mild’ 2009
influenza A(H1N1) pandemic was associated with substantial years
of life lost due to mortality in younger age groups [3].
Patients with sub-optimal immune function due to disease or
therapy (the immunocompromised) are recognised to be at
increased risk from influenza-related complications, and are
recommended for annual vaccination in many national vaccina-
tion guidelines. Concerns about influenza within immunocom-
promised populations include an impaired response to vaccination
and higher risk of complicated infection with increased mortality
[4], greater and prolonged virus shedding with implications for
control of transmission [5–8], the emergence of resistance to
antiviral agents [9] and possible adverse effects of vaccination. The
balance between potential benefit and harm resulting from
vaccinating these groups has been hard to establish, with previous
reviews finding few studies offering incontrovertible evidence of
clinical protection [10–13]. There is uncertainty around thresholds
for defining immunocompromise and the extent to which
underlying aetiologies vary in their susceptibility to influenza
and potentially their response to vaccine, with deference to clinical
opinion in many cases [14]. A high burden of illness was
recognised in immunocompromised patients during the 2009
influenza A(H1N1) pandemic, along with substantial nosocomial
disease, proclaiming the need to re-visit the evidence base for
influenza vaccination in these patients [8,15–21].
We conducted a systematic review and meta-analysis to assess
influenza vaccination for immunocompromised patients. We
report the primary analysis and its interpretation from a public
health policy perspective, to assess the overall evidence. A second
manuscript will be submitted for publication which reports a
secondary analysis of our data, stratified by aetiology of
immunocompromise.
Methods
An abbreviated study protocol is available from the National
Institute for Health Research international prospective register of
systematic reviews (PROSPERO) [22], and the full protocol and
PRISMA checklist are available as supporting information (see
Protocol S1 and Checklist S1). Minor amendments to the original
protocol were conducted to clarify the search strategy and
eligibility criteria.
The study population of interest comprised all persons
immunocompromised due to primary immunodeficiency (genetic
defects) or secondary immunodeficiency (such as HIV infection,
malignancy, or receipt of immunosuppressive drugs). Immuno-
compromised populations were derived from World Health
Organization (WHO) and United Kingdom (UK) Department of
Health immunisation policy to prevent influenza infection [14,23].
We additionally included malnutrition and tuberculosis as
conditions commonly associated with immunocompromise in
developing countries. Interventions of interest comprised vaccina-
tion against seasonal influenza or 2009 influenza A(H1N1)
pandemic; restricted to experimental designs for seasonal influenza
but with no limitation for pandemic studies where experimental
approaches would have been ethically unfeasible in most
circumstances. Comparative groups included vaccinated immu-
nocompetent controls (VICT) and immunocompromised patients
given placebo or no vaccination (PNV). Outcome measures
corresponded to four research questions relevant to this review:
prevention of clinically diagnosed influenza or influenza-like illness
(ILI) and laboratory confirmed influenza infection, serological
response, and adverse events associated with vaccination. Criteria
for inclusion and exclusion of studies, established in advance of
executing the search strategy, are presented in Table 1 and
information sources searched to identify relevant literature are
shown in Table 2.
Search strategy and study selection
Single reviewers conducted searches during January 2011,
based on the term construct used for MEDLINE (see Table S1),
which was subsequently adapted or translated for other informa-
tion sources as appropriate. No date limit for publication was
applied to studies of seasonal influenza whilst a limit of 2009–10
was applied to studies pertaining to the 2009 influenza A(H1N1)
pandemic. Results were limited to human subjects and language of
publication restricted to English, French, Japanese, Portuguese,
Spanish and Russian.
After removal of duplicates a three-stage screening process
applied the eligibility criteria to all records. Screening at title,
abstract and full text was managed primarily within EndNoteH
64.0.2 (Thomson Reuters, California, USA). Records in non-
compatible formats or non-English languages were manually
screened. Screening was undertaken by two reviewers in parallel,
with consensus by discussion and provision for arbitration by a
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third reviewer. Due to insufficient resources, Spanish and
Portuguese literature was screened by one reviewer.
Data collection
Data were extracted by two reviewers in parallel using a piloted
template, with consensus by discussion and provision for
arbitration by a third reviewer. No further data were sought from
corresponding authors of eligible studies. Items extracted for study
characteristics comprised country setting, objectives, design,
sample size, methods of recruitment, inclusion and exclusion
criteria, sequence generation, allocation, confounders and funding
source. Population items comprised description of study groups,
setting and stability of setting, age, sex, socioeconomic character-
istics and risk factors for exposure to influenza. Intervention items
comprised healthcare provider, setting in which health care
delivered, description of intervention or exposure, vaccination
type, route of administration, dosing schedule, and number of
subjects allocated to and receiving the intervention or exposure.
Table 1. Study eligibility criteria.
Inclusion criteria
Experimental studies or systematic reviews (6 meta-analyses) reporting data on the efficacy, effectiveness, immunological response or adverse effects associated with
influenza vaccination of immunocompromised patients to prevent infection from seasonal influenza or 2009 influenza A(H1N1) pandemic strain
Observational studies published during 2009 and 2010 reporting data on the efficacy, effectiveness, immunological response or adverse effects associated with
influenza vaccination of immunocompromised patients to prevent infection from 2009 influenza A(H1N1) pandemic strain
Studies which recruited individuals of any age from any setting who are immunocompromised whether due to primary immunodeficiency (genetic defects) or
secondary immunodeficiency (such as HIV infection, malignancy, poor nutritional status or use of immunosuppressive drugs)
No restriction is placed on the influenza vaccination dose, preparation, trade name, schedule or method of administration
Studies which report data from control or comparator treatments may include no vaccination, placebo vaccination or sham vaccination
Studies which have recruited immunocompromised patients and compare outcome measures with immunocompetent control study subjects
Studies which report data on at least one of the following outcome measures: rate of clinically diagnosed influenza or ILI/ITT patients, rate of laboratory confirmed
influenza or ITTI patients, immunological response to vaccination, and adverse effects associated with vaccination
Full text manuscripts of studies which are published in English, French, Spanish, Portuguese, Russian, or Japanese
Exclusion criteria
Any literature or search hit which does not describe outcome measures obtained from an experimental study, observational study, or systematic review (6 meta-
analysis)
Any systematic review (6 meta-analysis) which has been superseded by an updated evidence synthesis (such as updated reviews published by the Cochrane Library)
Studies which report outcome measures associated with vaccination against avian influenza
Studies which do not report follow-up data of patients within 12 months of intervention
Studies which have recruited less than 5 subjects to the intervention arm or exposed group
Studies which have not recruited immunocompromised patients which include those aetiologies described in the protocol
Studies which compare vaccination with an active comparator and which do not report data from a control group of study subjects
Studies which compare vaccination only by route of administration or dosing schedules
Studies which report data from patients with drug induced immunosuppression where less than 80% of the study group are receiving immunosuppressive treatment*
*Applied to respiratory and autoimmune conditions only; no specification of dosage or duration of therapy.
doi:10.1371/journal.pone.0029249.t001
Table 2. Information sources.
Category Source
Databases MEDLINE; EMBASE; CINAHL; Cochrane Central Register of Controlled Trials (CENTRAL); PubMed; WHO Regional Indexes; J-
STAGE (Japanese language); Banque de Données en Santé Publique (BDSP, French language); Index-F (Spanish language);
eLIBRARY (Russian language)
Evidence-based reviews Bandolier; Cochrane Library: Database of Systematic Reviews (CDSR), Database of Abstracts of Reviews of Effects (DARE),
National Health Service Health Technology Assessment (NHS HTA)
Guidelines NHS Evidence: NHS Clinical Knowledge Summaries, National Library of Guidelines
Grey literature Web of Science; NHS Evidence; OpenSIGLE; influenza vaccine manufacturers: GlaxoSmithKline, Novaratis, Sanofi Pasteur MSD,
Abbott, CSL Limited, Medimmune, Crucell, Baxter; European Vaccine Manufacturers (Brussels); International Federation of
Pharmaceutical Manufacturers Associations (Geneva/Zurich); consultation with domain expert (Bram Palache, Abbott)
Hand searching of journals Vaccine
Reference tracking Reference lists of all included studies
Citation tracking Web of Science (Science Citation Index); Google Scholar
Internet searching www.google.com; www.dh.gov.uk; www.hpa.org.uk; www.who.int; www.cdc.gov; www.flu.gov
doi:10.1371/journal.pone.0029249.t002
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Outcome items comprised definition, measurement tool, timing
and unit of measurements, blinding of assessors, duration of
follow-up, number of measurements made (including withdrawals,
exclusions and losses to follow-up), intervention and comparator
results, detail of statistical analyses performed, and control for
selection bias and confounding.
Extracted outcome data on immune response were classified
according to Committee for Human Medicinal Products (CHMP)
seroconversion and seroprotection criteria for each influenza
subtype patients were vaccinated against [24]. Studies were
excluded from meta-analysis if they did not provide data assessable
against CHMP criteria or did not draw blood for serology at any
time within 2–4 weeks post-vaccination. Geometric mean titre
(GMT) and mean fold increase of haemagglutination inhibition
(HI) levels pre- and post-vaccination were extracted. Adverse event
data on local and systemic events were extracted according to
CHMP criteria [24]. In addition, data on serious adverse events
[25] and disease progression or clinical impact of immunocom-
promising condition were also extracted.
Risk of bias in individual studies
Risk of bias was assessed at both study and outcome level using
tools produced by the Cochrane Collaboration [26] for experi-
mental and prospective cohort designs, Downs and Black [27] for
observational designs (excluding prospective cohort studies) and
the US Agency for Healthcare Research Quality (AHRQ) [28] for
systematic reviews. Assessments were undertaken in parallel by
two reviewers reaching consensus by discussion, with provision for
arbitration by a third reviewer. Abstract-only records were not
subject to assessment of risk of bias due to paucity of information.
Domain-based risk of bias was used to inform narrative synthesis,
thus avoiding overall scores in accordance with recommendations
[26,29].
Summary measures
Descriptive statistics were calculated using MicrosoftH Office
ExcelH 2007 version 12 (Microsoft Corporation, Richmond, USA).
Where feasible, odds ratios including 95% confidence intervals
and the standard error of the natural log odds ratio were
calculated for input into meta-analyses.
Synthesis of results
Primary analysis was designed to synthesize appraisal of
methodological quality and extracted study data by means of
tabulation, narrative and meta-analysis (where appropriate). With
the exception of serological outcome measures, data pertaining to
the 2009 influenza A(H1N1) pandemic were pooled together with
seasonal influenza data in accordance with the research aim to
assess overall evidence. Meta-analysis of pooled odds ratios
estimated the effect size of vaccinating immunocompromised
patients versus immunocompetent controls (VICT), and of
immunocompromised patients receiving vaccination versus those
receiving placebo or no vaccination (PNV). Meta-analyses were
conducted using StataH version 10 (StatCorp LP, Texas, USA)
initially using a random effects model. Analyses were re-executed
using a fixed effects model where heterogeneity was low (I2,40%)
and abandoned where heterogeneity was high (I2.85%). Statis-
tical significance of pooled odds was assumed at the 5% level and
assessed using the X2 test. Risk of publication bias for studies
subject to meta-analysis was assessed visually using Begg’s funnel
plots and quantified using Egger’s regression test. Sub-analysis
sought to utilise the UN inequality-adjusted Human Development
Index 2010 (UN HDI) [30] for stratification of countries by
quartile of human development to assess the strength of evidence
in low resource environments.
Results
Study selection and characteristics
Figure 1 provides an account of the study selection process in
the form of a PRISMA flow diagram [29]. The search strategy
initially yielded 9,960 records (of which 1,833 were duplicates);
7,627 records were excluded as a result of screening at title and
abstract stage. Reasons for exclusion of 293 records at full-text
screening are shown in Figure 1. Five records were unobtainable
at full text and therefore excluded [31–35]. Reference and citation
tracking identified a further 12 eligible records, providing 219
records for narrative analysis (five in Russian, three Japanese and
the remainder English). After exclusion of multiple reporting
(n = 10) 209 individual studies met review eligibility criteria
[11,12,36–252]; 16 pertained to vaccines against the 2009
influenza A(H1N1) pandemic virus [39,43,48,55,79,86,104,
170,181,188,212,223–225,232,243].
Characteristics of the eligible studies are summarised in Table 3.
These data have not been presented for each individual study due
to the volume of data extracted but are available on request. Of
note is the large quantity of available data from non-randomised
controlled trials (n = 137) and non-randomised clinical studies
(n = 43) in addition to the limited data available from countries in
medium or low categories of the UN HDI (n = 3). Sub-analysis by
resource setting was therefore abandoned due to insufficient data.
Immunocompromise due to human immunodeficiency syndrome
(HIV), cancer and transplant were approximately equally
represented with over 50 studies each, together accounting for
more than three quarters (78%) of aetiological groupings.
A median of sixty immunocompromised patients received active
influenza vaccination across the 209 studies (interquartile range
[IQR] 36 to 110). Studies typically administered the vaccine by
intramuscular injection (n = 138) with a minority utilising
intradermal (n = 20), subcutaneous (n = 2) and intranasal routes
(n = 3). Forty-nine studies did not report these data (most likely
intramuscular) and three studies used multiple routes of admin-
istration. The median intervention group size for included RCTs
was 55 (IQR 26 to 103) and the median placebo or no vaccination
group size was 24 (IQR 17 to 56). A median of 65 vaccinated
immunocompromised subjects were recruited (IQR 40 to 116) and
sources of funding were declared by 114 studies.
Risk of bias within studies
Figure S1 summarises the assessment of risk of bias for 191
included experimental studies and prospective cohort designs. The
majority of studies were judged at high risk of bias for sequence
generation and allocation concealment domains. However, this
finding is largely explained by only 23 RCTs meeting the protocol
eligibility criteria. Only 10% of RCTs were at high risk of bias due
to sequence generation or allocation concealment issues, although
risk of bias was unclear in the majority (60% and 80%
respectively). Risk of bias due to blinding of study participants,
personnel and outcome assessors reduced from 22% in all studies
to 5% in RCTs.
Table S2 summarises the assessment of risk of bias for two
included case series [48,232]. Bate et al (2010) scored highly within
the reporting domain of the risk of bias tool whilst Vazquez-
Alvarez et al (2010) scored poorly due to limited description of the
study characteristics including potential confounding variables.
Both studies scored poorly for external and internal validity.
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Table S3 summarises the assessment of risk of bias for three
included systematic reviews [11,12,42]. Risk of bias in all three
studies was generally low, although Atashili et al (2006) did not
assess quality and validity for included studies. Anema et at (2008)
and Atashili et al (2006) conducted meta-analyses for a pooled
estimate of the effectiveness of influenza vaccination in preventing
ILI or laboratory confirmed infection in HIV patients, both
including three prospective studies [190,222,247] while Atashili et
al (2006) additionally included a case control study [253].
Synthesis of results
Outcomes for all 209 individual studies cannot be presented due
to volume of data. We pooled studies for analyses according to
review questions, irrespective of aetiology of immunocompromise
(see discussion for comments on clinical heterogeneity). We
identified 47 studies reporting data pertaining to the prevention
of influenza-like illness, 16 on prevention of laboratory confirmed
influenza, 189 on immune response to vaccination and 152 on
adverse events or safety. Of these, we identified 6, 2, 12, and 11
studies respectively which reported outcomes pertaining to
vaccines against the 2009 influenza A(H1N1) pandemic virus.
Influenza-like illness. Meta-analysis pooled seven studies of
ILI reported in vaccinated immunocompromised patients
compared to PNV [59,97,159,190,202,222,232]. Figure 2 shows a
pooled effect size of 0.23 (95% CI 0.16 to 0.34; p,0.001) with low
statistical heterogeneity (I2 = 22.0%; p = not significant [NS]). Meta-
analysis also pooled two studies of ILI reported in vaccinated
immunocompromised patients compared to VICT [59,160].
Figure 2 shows a pooled effect size of 0.62 (95% CI 0.22 to 1.78;
p = NS) with low statistical heterogeneity (I2 = 12.3%; p = 0.286).
Two earlier meta-analyses considered vaccination impact on
incidence of ILI in immunocompromised patients. Atashili et al
(2006) pooled one RCT, two non-randomised studies and one
case-control study of ILI or laboratory confirmed influenza
compared to PNV, estimating a risk difference of 20.27 (95%
CI 20.11 to 20.42; p = 0.004) but with significant heterogeneity
(I2 = 76.8%; p = 0.003) [12]. To address methodological concerns
Anema et al (2008) performed the same analysis excluding the case-
control study, finding a risk ratio of 0.34 (95% CI 0.18 to 0.64;
p = ,0.001) again with significant heterogeneity (I2 = 73%;
p = 0.02) [42].
Of those studies unsuitable for meta-analysis, we identified 22
interventional studies and one observational design where no cases
of ILI were found in vaccinated immunocompromised patients
(including two RCTs with a PNV comparator and 13 non-
randomised studies with VICT controls). The remaining studies
we identified typically showed a low incident case number of cases,
with some noteworthy exceptions. Cumulative incidence of ILI in
vaccinated renal transplant recipients immunosuppressed with
azathioprine is reported as 5.4% and 8.3% for those on
mycophenolate mofetil, compared to 8.1% in healthy controls
[204]. The number of upper respiratory tract infections in
vaccinated paediatric cancer patients completing therapy within
six months of randomisation was 0.5260.79 (mean 6 standard
deviation), compared to 2.7361.49 in unvaccinated patients [97].
The inter-group difference reduced to 0.4660.73 in patients off
therapy for 6–24 months, compared to 0.6960.73 in unvaccinated
patients.
Laboratory confirmed influenza. Meta-analysis pooled
two studies in vaccinated subjects with HIV compared to PNV
Figure 1. Summary of study selection process.
doi:10.1371/journal.pone.0029249.g001
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[222,247]. Figure 2 shows a pooled effect size of 0.15 (95% CI
0.03 to 0.63; p = 0.01) with moderate statistical heterogeneity
(I2 = 50.4%; p = NS).
We found limited data from non-randomised studies showing
very low numbers of incident cases of laboratory confirmed
influenza post vaccination in immunocompromised patients. Nine
studies reported no cases during follow-up, and two studies found a
single case each. A study by Tasker and colleagues [222] reported
a protective efficacy of symptomatic laboratory confirmed
influenza A of 100% (95% CI 73% to 100%) in HIV patients
compared to PNV controls.
Immune response to vaccination. Data on immune
response to vaccination for each influenza subtype were pooled
for meta-analyses based on CHMP definitions of seroconversion
or seroprotection [24] and are summarised in Table 4 with the
associated forest plots provided in Figure S2. Table 4 lists several
highly significant pooled effects, although moderate to important
levels of statistical heterogeneity were typically present.
Seroconversion (SC1) with a PNV comparator group was more
likely in patients receiving immunologically active vaccine,
although statistically significant only for influenza B. Odds of
seroconversion (SC2) following vaccination against seasonal
A(H1N1) and A(H3N2) were statistically equivalent between
immunocompromised patients and VICT controls, although the
likely estimate of effect suggests an inferior response in patients.
Vaccination against pandemic A/H1N1/California/7/2009
resulted in lower but non-significant odds of seroprotection
compared to VICT controls although the two pooled studies
gave an adjuvanted [60] and non-adjuvanted [154] vaccine in
different populations, with significant statistical heterogeneity.
Of the 85 studies unsuitable for meta-analysis reporting rates of
seroconversion, seroprotection or mean geometric increase in HI
titre based on serology within 2–4 weeks, many were single-arm
but broadly supported the above findings. Notably, statistically
equivalent rates of seroconversion (SC1) were found to influenza
A(H3N2) and B in patients with primary immunodeficiency [229]
and to pandemic A/H1N1/California/7/2009 in paediatric
cancer patients [43], both compared to VICT controls. Similar
findings were observed in studies comparing seroprotection rates
[120,158]. Further to those subject to meta-analysis only one study
reporting serological data with a PNV comparator was identified,
but this RCT lacked sufficient description of the control group to
permit interpretation [58]. Most studies reporting GMT showed
vaccinating immunocompromised patients was associated with a
$2.5 fold rise, as per CHMP assessment criteria [254]. Immune
response among cancer patients vaccinated against pandemic A/
H1N1/California/07/2009 using adjuvanted [43] and unspecified
[243] vaccines was statistically comparable to that of immuno-
competent controls.
Adverse events and safety. Adverse event data were
unsuitable for meta-analysis owing to difficulty in accurately
identifying cases and denominator counts, and potential for bias
due to post hoc selection of reported outcomes. Local and systemic
adverse events were mapped to CHMP criteria [24] in 34 studies.
These were generally self-reported, using diary cards or telephone
follow-up. Where feasible median adverse event rates were
calculated (see Table 5), in addition six studies each reported
,3 cases of fever.
Eighty-seven studies reported clinical or laboratory markers of
vaccination impact on the underlying immunosuppressive condi-
tion. These included CD4+ count and HIV load in HIV-positive
patients, relapse and complication rate in cancer patients, allograft
rejection rate in transplant patients, disease activity scores in
patients with autoimmune conditions and lung function tests in
respiratory patients. We did not identify consistent evidence of
disease progression or worsening of clinical symptoms related to
underlying immunosuppressive condition following vaccination.
Incidence of serious adverse events was reported in 21 studies,
although only 11 of these included a control group. Three
hospitalisations occurred in patients with HIV [136] and one
transient ischaemic attack in a separate study, which did not
specify whether the case was HIV-positive or a healthy control
[94]. Madan et al (2008) report biopsy-proven allograft rejection
within six months of vaccination in four paediatric liver transplant
recipients [158]. None of these events (nor those described in other
eligible studies) was deemed due to influenza vaccination
[43,94,136,158]. Five of 54 paediatric cancer patients developed
fever within 48 hours of receiving an adjuvanted vaccination for
influenza A/H1N1/California/07/2009. However, whether this
was a consequence of vaccination, underlying cancer or
concomitant chemotherapy or infection was indeterminable [48].
Risk of bias across studies
Risk of publication bias was assessed using Begg’s funnel plot
and confirmed statistically where feasible using Egger’s test. There
was no evidence of biased reporting among studies subject to
meta-analysis.
Table 3. Summary of study characteristics (n = 209).
Characteristic Number of studies
Study design
Systematic reviews 6 meta-analyses 3
Randomised controlled trials 23
Non-randomised controlled trials 137
Non-randomised clinical studies 43
Prospective cohort studies 1
Case series 2
Setting of conduct
Community or primary care 5
Outpatient department or hospital clinic 127
Other 3
Not stated 74
UN inequality-adjusted Human
Development Index 2010
Very high 186
High 16
Medium 3
Low 0
No data 4
Study population (aetiology of immunocompromise)*
Human immunodeficiency virus (HIV) infection 58
Cancers 56
Transplant recipients 52
Autoimmune diseases receiving
immunosuppressive therapy
34
Respiratory diseases receiving
immunosuppressive therapy
5
Other 7
*Three studies recruited multiple groups of immunocompromised patients
[52,89,119].
doi:10.1371/journal.pone.0029249.t003
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Discussion
Summary of evidence
This systematic review is the first to consider clinical and
serologic outcomes following influenza vaccination in immuno-
compromised patients, incorporating data from the 2009
pandemic period. Our results suggest that vaccinating immuno-
compromised patients against influenza provides clinical protec-
tion from influenza-like illness and laboratory confirmed infection
compared to placebo or no vaccination, and the rate of
symptomatic disease is comparable to that observed in vaccinated
healthy controls. The pooled odds of seroconversion were
consistently higher in vaccinated patients compared to PNV
controls, although statistical superiority was demonstrated only
for influenza B. Conversely, the odds of seroconversion (SC1) and
seroprotection conferred by vaccination were consistently and
significantly lower in patients compared to VICT controls for
seasonal influenza A(H1N1), A(H3N2) and B (see Table 4). The
data reviewed offer no consistent evidence of safety concerns,
disease progression or serious adverse events following influenza
vaccination in immunocompromised populations. Table 5 sug-
gests a higher median rate of malaise in vaccinated immuno-
compromised patients compared to VICT controls (23.6% vs
12.0%), however malaise is also elevated in PNV controls
implying an association with the underlying immunocompro-
mised state.
Figure 2. Forest plot for studies on influenza-like illness and laboratory confirmed influenza. Legend: (A) = influenza-like illness (placebo
or no vaccination comparator); (B) = influenza-like illness (vaccinated immunocompetent controls); (C) = laboratory confirmed influenza (placebo or
no vaccination comparator). Note that each of the three plots shown has different scaled x-axes.
doi:10.1371/journal.pone.0029249.g002
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Limitations
Risk of bias and confounding. Many of the 209 eligible
studies were at unclear or high risk of bias across most domains
and the number of RCTs was relatively small (n = 23). The
majority of studies (n = 137) were non-randomised trials that
included a control group, but without robust randomisation
selection bias between study arms cannot be excluded. Non-
randomised designs may also introduce unbalanced confounding
variables, and given that analyses were commonly reported
unadjusted, these may reasonably influence the reported effect
sizes for each pooled outcome measure. Potential confounders
were anticipated and specified in the study protocol. Included
cases series conducted during the 2009 influenza A(H1N1)
pandemic are likewise at high risk of selection bias. Stratification
of meta-analyses by risk of bias was unfeasible due to concerns
with selecting a specific domain for classifying studies as ‘low’ or
‘high’. Adverse event data presented in Table 5 do not take
account of numerous studies broadly stating absence of adverse
events in vaccinated groups, potentially introducing reporting bias.
Heterogeneity. Moderate to high levels of statistical
heterogeneity were present in many of the reported meta-
analyses, reaching significance on numerous occasions. Even
where effect sizes are consistent, clinical heterogeneity may
continue to challenge the validity of meta-analysis. Potential
confounders related to aetiology of immunocompromise or
intervention characteristics may be responsible for such
heterogeneity. This includes pooling of data arising from the
2009 influenza A(H1N1) pandemic vaccine (commonly
monovalent, sometimes adjuvanted) with seasonal vaccines
although ,10% of studies overall involved such vaccines, only
one study was included in the ILI meta-analysis (PNV
comparator), and the two studies reporting data on prevention
of laboratory confirmed influenza offered narrative information
only. Previous exposure to influenza vaccination, timing of vaccine
administration (in relation to changes in administration of
immunosuppressive therapy or disease state) and
immunosenescence may also be important effect modifiers
contributing to heterogeneity between the reported outcome
measures. Similarly, matching between vaccine and wild type
influenza strains is likely to introduce a degree of inter-seasonal
variability; however, this does not affect our conclusions in terms
of public health policy as these are typically designed to provide
Table 4. Summary of meta-analyses for immune response to vaccination.
Outcome measure Influenza subtype Comparator Number of studies Pooled ES (95% CI) p value of ES I2 (%) p value of I2
SC1 A(H1N1) (S) VICT 50* 0.55 (0.43 to 0.71) ,0.001 53.2 ,0.001
SC1 A(H3N2) VICT 47* 0.55 (0.41 to 0.73) ,0.001 66.9 ,0.001
SC1 B VICT 44* 0.48 (0.36 to 0.62) ,0.001 54.3 ,0.001
SC1 A(H1N1) (S) PNV 3 3.90 (0.42 to 36.64) NS 77.8 0.01
SC1 A(H3N2) PNV 3 10.93 (0.92 to 129.80) NS 82.5 0.003
SC1 B PNV 2 9.17 (1.05 to 79.97) 0.05 72.7 NS
SC2 A(H1N1) (S) VICT 6 0.65 (0.39 to 1.09) NS 13.6 NS
SC2 A(H3N2) VICT 8 0.60 (0.25 to 1.43) NS 63.9 0.007
SC2 B VICT 8 0.42 (0.19 to 0.94) 0.04 69.8 0.002
SP A(H1N1) (P) VICT 2 0.22 (0.02 to 2.75) NS 80.4 0.02
SP A(H1N1) (S) VICT 37* 0.36 (0.26 to 0.51) ,0.001 56.9 ,0.001
SP A(H3N2) VICT 35* 0.39 (0.26 to 0.59) ,0.001 64.1 ,0.001
SP B VICT 37* 0.37 (0.25 to 0.53) ,0.001 65.1 ,0.001
* = some studies contributed two sets of data included in this meta-analysis; (S) = seasonal; (P) = pandemic; ES = effect size; CI = confidence interval; SC1 = seroconversion
($4 fold rise post vaccination); SC2 = seroconversion (,1:40 to $1:40 haemagglutination inhibition titre); SP = seroprotection ($1:40 haemagglutination inhibition titre
post vaccination); VICT = vaccinated immunocompetent controls; PNV = placebo or no vaccination; NS = not statistically significant. See Figure S2 for citation details.
doi:10.1371/journal.pone.0029249.t004
Table 5. Median adverse event rate by CHMP criteria.
Adverse event IC patients (%) VICT controls (%) PNV controls (%)
Local
Ecchymosis 3.1 (2.0 to 4.2; n = 2) 0.0 (0.0 to 0.0; n = 1) –
Induration 18.9 (10.2 to 30.0; n = 5) 11.0 (6.3 to 15.0; n = 3) –
Systemic
Fever 7.1 (0.0 to 23.3; n = 14) 5.0 (0.0 to 16.7; n = 5) 10.2 (10.0 to 10.3; n = 2)
Malaise 23.6 (0.8 to 44.0; n = 8) 12.0 (0.0 to 25.9; n = 5) 22.1 (20.0 to 24.1; n = 2)
Shivering 10.2 (10.2 to 10.2; n = 1) 16.3 (16.3 to 16.3; n = 1) –
Values in parentheses show the reported range of adverse events and number of studies; IC = immunocompromised; VICT = vaccinated immunocompetent;
PNV = placebo or no vaccination.
doi:10.1371/journal.pone.0029249.t005
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consistent advice over multiple seasons. Our analyses reported
separately by aetiology of immunocompromise provide a degree of
sensitivity testing for pooled results.
Other limitations. Paucity of data limited or prevented
some analyses. There were insufficient data to adequately report
on seroconversion or seroprotection with a PNV comparator. The
planned sub-analysis of evidence from resource-poor countries was
abandoned due to insufficient data arising from this setting. In
addition, it is now recognised that a large proportion of the
population aged $55 years probably had some degree of pre-
existing immunity to the 2009 influenza A(H1N1) pandemic
strain, adding further difficulty to the interpretation of data from
the pandemic period [255]. We recognise CHMP criteria for
serological response to vaccination are based on healthy volunteers
aged 18 to 60 years thus may not reflect expected rates of
clinical protection observed in vaccinated immunocompromised
populations [256].
Implications for public health practice
Our data favour a policy of routinely recommending influenza
vaccination to immunocompromised patient groups, who may be
at higher risk of influenza and its complications [14,257]. Many
authorities, such as the UK Joint Committee on Vaccination and
Immunisation and the US Advisory Committee on Immunization
Practices, already recommend vaccinating immunocompromised
patients and household or close contacts against influenza to
minimise transmission [14,257]. However, uptake of this inter-
vention is currently unclear but, where data exist, these suggest
sub-optimal coverage [258]. Although our findings indicate some
mild and self-limiting adverse effects following vaccination, policies
should acknowledge these may occur with greater frequency in
certain patient groups, and make suitable provision for clinical
discretion. Management of infection in immunocompromised
patients can be complicated by limited effectiveness of pharma-
cological therapies and vaccination carries the additional benefit of
mitigating emergence of resistance to antiviral agents [9].
Implications for further research
Methodological limitations affecting the current evidence base
mandates new robust studies assessing the incidence of ILI and
laboratory confirmed influenza in vaccinated immunocompro-
mised patients. Similarly, robust studies are needed to inform
revised CHMP seroconversion and seroprotection criteria appli-
cable to immunocompromised patients. Further primary research
is warranted to quantify factors contributing to heterogeneity,
including the utility of second ‘booster’ doses, immunological
adjuvants and degree of immunosuppression on rates of clinical
protection and response to vaccination. Systematic reviews and
meta-analyses are indicated to assess the impact of vaccinating
immunocompromised patients on influenza-related morbidity and
mortality. In addition, resource poor countries should be
supported to conduct robust studies of influenza vaccination in
their immunocompromised populations. Proportionally different
comorbidities such as malnutrition or co-infection with HIV may
be encountered and response to vaccination among indigenous
groups and ethnic minorities may differ in these settings compared
to developed countries.
Conclusion
Our systematic review and meta-analyses suggest immunocom-
promised patients do manifest an immune response to vaccination
that, while not as vigorous as that of healthy controls, probably
confers a similar level of clinical protection against influenza and,
importantly, does so without causing excess harm. Limitations
including potential for bias and confounding and the presence of
statistical or clinical heterogeneity mean the evidence for these
assertions is generally weak, but the direction of effects are
remarkably consistent. Nevertheless, our study supports national
and international public health policy recommendations for the
targeting of immunocompromised patients for influenza vaccina-
tion.
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